← Other lipid agents × lipids

TrialJournal of the American Heart Association2025

Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.

Rahul Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT01492361. The trial’s primary report, PMID 30415628, speaks for it on the map; the numbers here are shown and do not vote.

  • Icosapent ethyllooks good hereLower primary composite end point.Weak evidence: one subgroup.

What the trial testedrandomised · 8,175 people · 2025

One subgroup

May have lowered primary composite end point in LDL-C <55 mg/dL

Doesn’t vote: a later paper about the trial

−34%−50% to −13%

icosapent ethyl vs placebo, in LDL-C <55 mg/dL

Bigger than 7 in 10 on the map

As reported

HR 0.66, 95% CI 0.50–0.87

+1 more in the walkthrough ↓

Who was studied, and how

8,179people in the Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease trial, from 2011
8,175of them with cardiovascular disease, in this paper

Among LDL-C <55 mg/dL, the trial randomly assignedassigned by chance

icosapent ethyl
placebo

May have lowered primary composite end point−34%

randomised · one subgroup

the abstract, start to end

… in the placebo group (hazard ratio [HR], 0.66 [95% CI, 0.50-0.87]; absolute risk reduction, 6.6%; CONCLUSIONS: Among …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Primary composite end pointicosapent ethyl vs placebo, in LDL-C <55 mg/dL
HR 0.660.50–0.87
Primary composite end pointicosapent ethyl vs placebo, in LDL-C <55 mg/dL
−6.60
Other lipid agentsLipids
1 / 4

10 papers cite it

2025
2026
this papercites it

The trial

NCT01492361phase 38,179 enrolled2011a later paper about it
Full record →Abstract, authors, funding and every citing paper · PMID 39968782